KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBIT (2017 - 2025)

Bionano Genomics (BNGO) has disclosed EBIT for 9 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 71.87% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2025, up 76.49% year-over-year, with the annual reading at -$5.5 million for FY2025, 76.49% up from the prior year.
  • EBIT hit $19.3 million in Q4 2025 for Bionano Genomics, up from -$8.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $68.5 million in Q4 2024 to a low of -$113.2 million in Q3 2023.
  • Historically, EBIT has averaged -$22.7 million across 5 years, with a median of -$26.9 million in 2021.
  • Biggest five-year swings in EBIT: crashed 252.15% in 2023 and later surged 374.62% in 2024.
  • Year by year, EBIT stood at -$28.8 million in 2021, then tumbled by 30.38% to -$37.5 million in 2022, then soared by 33.51% to -$25.0 million in 2023, then soared by 374.62% to $68.5 million in 2024, then tumbled by 71.87% to $19.3 million in 2025.
  • Business Quant data shows EBIT for BNGO at $19.3 million in Q4 2025, -$8.5 million in Q3 2025, and -$7.8 million in Q2 2025.